CG
GLMD icon

Cutler Group’s Galmed Pharmaceuticals GLMD Stock Holding History

Cutler Group’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-32
Closed -$1K – 4549
2020
Q1 		$1K Buy
32
+10
+45% +$9.51K ﹤0.01% 3702
2019
Q4 		$3K Buy
+22
New +$18.9K ﹤0.01% 3277

Other funds holding GLMD

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Cutler Group's GLMD Position: Q4 2020 in Review

Cutler Group sold out of Galmed Pharmaceuticals (GLMD) in Q4 2020, closing a stake of 1 share — an estimated $624 sold.

Cutler Group first reported a position in GLMD in Q2 2018 and held it in 7 quarters. The position peaked at $74K in Q3 2018. 21 funds tracked by Wall St. Rank hold GLMD as of Q4 2020.

  • Cutler Group reported no remaining Galmed Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Cutler Group sold 1 Galmed Pharmaceuticals share in Q4 2020, an estimated $624.
  • Cutler Group first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 7 quarters.
  • Cutler Group's Galmed Pharmaceuticals position peaked at $74K in Q3 2018.
  • 21 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2020.

Based on Cutler Group's 13F filing for Q4 2020, filed 21 Jan 2021.